Burcon Announces Closing of First Tranche of Non-Brokered Private Placement of Convertible Debentures
Executive Summary
- Burcon NutraScience Corp. closed the first tranche of a non‑brokered private placement for up to $6.3 million in convertible debentures, receiving $1.25 million in gross proceeds from its manufacturing partner owners.
- The financing is intended to accelerate production, inventory build‑up, and infrastructure investments, as well as repay a short‑term loan disclosed on November 12, 2025.
- A second tranche is expected to close around February 24, 2026 pending shareholder approval at the special meeting scheduled for February 20, 2026.
Key Details
- Private Placement Structure
- Total aggregate principal amount: up to $6.3 million.
- Insiders and manufacturing partner owners committed to a minimum of $5.0 million participation.
-
First tranche closed with $1.25 million gross proceeds (direct investment from manufacturing partner owners).
-
Convertible Debenture Terms
- Principal per debenture: $1,000.
- Interest rate: 15% per annum, payable in full at maturity.
- Maturity: 48 months after issuance; principal and accrued interest payable in cash.
- Conversion price: $1.60 per share (option to convert into common shares or pre‑funded warrants).
-
Pre‑funded warrant exercise price: $0.00001 per PF Share.
-
Accelerated Prepayment / Conversion Feature
- If the VWAP of Burcon’s shares on the TSX exceeds $3.20 (200% of conversion price) for 14 consecutive trading days after the first anniversary, the company may prepay principal and interest.
-
Holders have 30 days to accept prepayment; otherwise, the company may accelerate conversion into shares or PF warrants.
-
Resale Restrictions
- Convertible debentures, underlying shares, and PF warrants are subject to a four‑month plus one day statutory resale restriction under Canadian securities law.
-
Securities are “restricted” in the U.S.; not registered under the U.S. Securities Act.
-
Finder’s Fee
-
Company may pay a cash finder’s fee up to 4.0% of gross proceeds to any finders introducing investors.
-
Use of Proceeds
- Accelerate growth via investments in inventory, labor, and production capability.
- Fund future infrastructure projects anticipating higher customer demand.
- General corporate purposes.
-
Repay the short‑term loan disclosed on November 12, 2025.
-
Shareholder Approval & Closing Timeline
- Shareholder approval required for final tranche due to insider participation exceeding 20% of outstanding shares.
-
Special shareholders’ meeting scheduled for February 20, 2026; final tranche expected to close ≈ February 24, 2026, subject to regulatory approvals and execution of subscription agreements.
-
Regulatory & Related‑Party Considerations
- Transaction qualifies as a related‑party transaction under MI 61‑101; company will rely on exemptions from formal valuation and minority shareholder approval because insider participation is <25% of market cap.
- No U.S. registration; securities may not be offered or sold in the United States absent exemption.
Notable Quotes
- “The strong support for this financing, particularly from our insiders and manufacturing partner owners, reflects confidence in Burcon's strategy and progress,” said Kip Underwood, CEO.
- “The closing of this first tranche strengthens our financial position and enables us to accelerate production and ingredient sales to meet increasing customer demand.” – Kip Underwood, CEO.